MOLINA ARTURO MD 4
4 · Protagonist Therapeutics, Inc · Filed Jun 11, 2025
Insider Transaction Report
Form 4
MOLINA ARTURO MD
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-06-09−10,000→ 85,971 totalExercise: $8.04Exp: 2032-11-15→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2025-06-09$8.04/sh+10,000$80,400→ 93,892 total - Sale
Common Stock
2025-06-09$55.51/sh−10,000$555,100→ 83,892 total - Exercise/Conversion
Common Stock
2025-06-10$8.04/sh+10,000$80,400→ 93,892 total - Sale
Common Stock
2025-06-10$57.03/sh−10,000$570,300→ 83,892 total - Exercise/Conversion
Stock Option (right to buy)
2025-06-10−10,000→ 75,971 totalExercise: $8.04Exp: 2032-11-15→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.18 to $55.75. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.665 to $57.48. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer.